Since SE strategy was reported for the first time to successfully isolate lung cancer CTCs in 2009 [30], substantial improvement has been made to render its maximum efficiency and optimized flexibility for enrichment of CTCs, DTCs and CTM in various specimens of different types of cancer patients [31] or tumor mouse models [9], despite how EpCAM is heterogeneously expressed or cell size is varied. The gene discussed is EPCAM; the disease is lung carcinoma.